AP 158
Latest Information Update: 30 Apr 2007
Price :
$50 *
At a glance
- Originator Emergent BioDefense Operations Lansing
- Developer United States Army Medical Research Institute of Infectious Diseases
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anthrax; Enterococcal infections; Listeria infections; Staphylococcal infections
Most Recent Events
- 30 Apr 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
- 30 Apr 2007 Discontinued - Preclinical for Enterococcal infections in USA (Topical)
- 30 Apr 2007 Discontinued - Preclinical for Listeria infections in USA (unspecified route)